Clinical outcomes and breast cancer subtypes in patients with brain metastases

Onkologie

Volumn 33, Issue 4, 2010, Pages 146-152

  Kwon, Hyuk Chan ^a,b   Oh, Sung Yong ^a   Kim, Sung Hyun ^a   Lee, Suee ^a   Kwon, Kyung A ^a   Choi, Young Jin ^c   Cho, Goon Jae ^c   Kim, Yang Soo ^d   Lee, Miri ^b   Lee, Jin Hwa ^b   Kim, Dae Cheol ^a,b   Lee, Hyung Sik ^b   Cho, Se Heon ^b   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d Kosin University   (South Korea)

Author keywords

Brain metastases; Breast cancer; Subtypes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; COMORBIDITY; FEMALE; HUMANS; KOREA; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 77953747109     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000286281     Document Type: Article

References (21)

1. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617.
2. Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM, Farace E, Fiveash JB, Lang FF, Lopes MB, Markert JM, Schiff D, Siomin V, Tatter SB, Vogelbaum MA: Brain metastases. Curr Probl Surg 2004;41:665-741.
3. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J, Cheung KL: Brain metastases from breast cancer: Identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004;16:345-349.
4. Cheng X, Hung MC: Breast cancer brain metastases. Cancer Metastasis Rev 2007;26:635-643.
5. Lin NU, Winer EP: Brain metastases: The HER2 paradigm. Clin Cancer Res 2007;13:1648-1655.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
7. Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005;23:7350-7360.
8. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-226.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
11. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J: Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
12. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW: Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 2008;112:2359-2367.
13. Fromm S, Bartsch R, Rudas M, de Vries A, Wenzel C, Steger GG, Zielinski CC, Poetter R, Dieckmann K: Factors influencing the time to development of brain metastases in breast cancer. Breast 2008;17:512-516.
14. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E: Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007;110:2640-2647.
15. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002;359:131-132. (Pubitemid 34112543)
16. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH: Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009;100:894-900.
17. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
18. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20: 621-627.
19. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A: Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008;19:1561-1565.
20. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.
21. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-1999.